Bronchopulmonary Dysplasia Treatment Market Growth – Trends & Forecast 2025 to 2035 

Bronchopulmonary Dysplasia Treatment Market Outlook 2025 to 2035

The market is expected to reach approximately USD 434.1 million in 2025 and expand to around USD 788.2 million by 2035, reflecting a compound annual growth rate (CAGR) of 6.1% over the forecast period.

The Bronchopulmonary Dysplasia (BPD) Treatment Market is experiencing a structural shift, stimulated by the growing clinical need to treat chronic lung disease in premature infants with immature lungs. As neonatal intensive care units increasingly receive preterm births, demand for specific and combinational drug regimens-specifically bronchodilators, diuretics, and surfactant therapies-has increased.

The market growth is well-rubbed against hospital-based protocol changes towards early intervention treatments, such as nitric oxide treatment and protein replacement. Moreover, stem cell treatment is picking up pace as a regenerative therapy for intractable cases of BPD that are not responsive to standard care.

Treatment providers are paying growing attention to integrated respiratory management channels through critical care units and specialist nursing homes, which is transforming the end-user landscape. With advances in neonatal monitoring and drug response assessment, drug formulation and respiratory care delivery stakeholders are competing to maximize BPD treatment effectiveness, driving the market into a stage of fast clinical and commercial growth.

Market Metrics

Metric	Value
Industry Size (2025E)	USD 434.1 million
Industry Value (2035F)	USD 788.2 million
CAGR (2025 to 2035)	6.1%

From 2020 through 2024, the Bronchopulmonary Dysplasia (BPD) Treatment Market saw consistent clinical uptake, underpinned chiefly by increasing cases of preterm birth and higher diagnostic sensitivity for neonatal respiratory diseases. Hospitals in this phase started preferring diuretics and bronchodilators as initial pharmacological management, with steroid treatment continuing steady for the resolution of inflammation.

Nitric oxide therapy became more clinically accepted, especially in Level III NICUs, due to its capacity for improved oxygenation in severe cases of BPD. Surfactant therapy was still the standard, but research-oriented methods such as stem cell therapy started emerging into early trials. The decade also witnessed the extension of respiratory care services to pediatric patients following discharge from the hospital.

Regional Market Trends

North America

• Currently, North America, with the United States and Canada dominates the Bronchopulmonary Dysplasia (BPD) Treatment Market owing to rigorous constitutional-preterm neonatal care protocols established in tertiary and quaternary healthcare settings. A major factor in the region is the high survival rate of extremely low birth weight (ELBW) infants, resulting in an increased clinical need for long-term pulmonary management strategies. Hospitals are moving toward personalized pharmacological combinations-especially bronchodilators and immunomodulators to manage evolving BPD phenotypes.
• The proliferation of critical care centers with Level III and IV NICUs has facilitated the utilization of advanced therapy types such as nitric oxide and stem cell therapy. Pediatric pulmonologists and neonatologists in North America are also at the leading edge of trials of surfactant homeostasis and protein replacement therapy, which may be impacting rates of clinical adoption. There is a growing trend of multi-disciplinary treatment frameworks, with respiratory therapy, nutritionists, and pediatricians combining to tackle long-term morbidity in BPD survivors further underpinning end-user investments.

Europe

• The Bronchopulmonary Dysplasia (BPD) Treatment Market in Europe is progressing due to high regional collaborations between specialized drug makers namely specializing in neonatal diseases and pediatric research institutes. Countries including Germany, France, and the Netherlands are also taking the lead by embedding multidisciplinary BPD care pathways within hospital and nursing home ecosystems. In fact, the European paradigm is largely focused on early diagnostic stratification for BPD, which allows for clinicians to segregate mild, moderate, and severe BPD at an earlier point in the treatment lifecycle.
• This stratification informs the selective application of surfactant homeostasis medications and diuretics in hospital settings. Furthermore, in light of the fact that long-term support programs already employ supplemental oxygen in addition to protein replacement therapy in the treatment of ventilator-dependent infants in Europe, a broader perception of the potential induced by long-term deficiency in the protein pool becomes apparent. The increasing focus on post-discharge respiratory therapy in homecare and step-down facilities are also advancing the importance of nursing homes and critical care center throughout the region. Beyond international guidelines, Europe’s regional health networks encourage data-sharing programs that promote rapid iteration of clinical protocols for novel therapies, and may thus be a driving force behind a balanced response of the BPD treatment market to evolving neonatal respiratory needs.

Asia-Pacific

• The BPD treatment market in Asia is pick up pace due to rising preterm birth globally and improvement in neonatal survival rates due to BPD treatment outpacing the step-in of infrastructure in BPD treatment that is majorly observed in countries like India and China. The difference is a market gap filled with scalable respiratory interventions and pharmacological approaches for treating chronic lung disorders in neonates. More recently, inhaled bronchodilators and steroids provided as early first steps of treatment of pulmonary inflammation in premature infants have also been increasingly implemented by hospitals.
• Additionally, innovation hubs at the regional levels, particularly with countries like south Korea, Japan are fast-tracking their research on stem cell therapy for regenerative lung applications which in turn clouds the future to more advanced therapy adoption. Pediatric critical care centers and nursing homes are transforming into specialized BPD recovery units, where therapies such as long-term oxygen support and protein supplementation are made available. A key driver across the region is the operational pivot to decentralized care delivery models that can enable resource-constrained centers to deliver simple BPD care protocols while advanced therapies and cases are centralized for care in regional referral hospitals. This model is allowing for increased market penetration and uptake of drug-based and therapy-based interventions.

Challenges and Opportunities

Challenges

Scalability limits of stem cell and nitric oxide therapies hinder broader adoption in developing markets

While stem cell and nitric oxide therapies are providing clinically favorable outcomes for severe cases of BPD, their application is limited by infrastructure and cost constraints. These modern interventions are largely available in tertiary care hospitals that have the capacity of specialized neonatal units but many low- and middle-income countries are not adequately catered for in this respect.

In areas where there is a high prevalence of preterm births, the lack of trained staff, storage systems, and continuous monitoring ability limits the real-world employment of such therapies. Moreover, operational restrictions in decentralized care environments impede the integration of these advanced options into routine neonatal practice.

This creates a dichotomy in the global market, with access in developing countries strongly focused on low-cost drug classes such as bronchodilators and diuretics. This gap is hampering the innovation-led expansion of the market, and is restricting treatment outcomes in high-need geographies.

Opportunities

Combinational therapy models drive long-term clinical and commercial value in BPD care

Newly emerging science on sequential and combinational treatment pathways are reshaping the BPD treatment landscape such that interventions become incremental and outcome-driven. Such regimens typically consist of a structured sequence of bronchodilators, surfactants and protein replacements, tailored to the fibrotic disease trajectory of the individual.

Such protocols have had positive impacts in terms of reducing mechanical ventilation dependency, promoting alveolar development and inflammation in both preventative and established BPD. Institutions with advanced neonatal research capabilities are pursuing testing of these strategies, with the advancement of fixed-dose combination formulations in clinical evaluation.

Growing interest from pharmaceutical players in these types of multi-action therapies are also setting the stage for commercial-scale solutions. With its unique focus on personalized, outcome-based treatment architecture, not only does this increase the chances of recovery but it also slashes hospitalization time and costs, realising long term clinical and economic value at both high-resource and tier two/three healthcare settings.

Bronchopulmonary Dysplasia Treatment Market Overview (2020 to 2024) and Future Projections (2025 to 2035)

From 2020 through 2024, the bronchopulmonary dysplasia (bpd) treatment market remained pro-COVID relative with high adoption of conventional pharmacological therapies like, Diuretics, bronchodilators, and steroids, due to the recent entry of advanced therapies and infrastructure related barriers that prevent high adoption and high cost of treatment. Treatment pathways were primarily linear; NICU-based pathways were centered on symptom control and ventilator weaning.

Conversely, the 2025 to 2035 vision is a paradigm shift towards combination-based and sequential models of therapy, incorporating surfactants, protein replacements, and new stem cell therapies. This is due to an increased focus on long-term pulmonary healing and minimizing post-discharge morbidity. Pediatric recovery facilities and nursing homes are becoming active care delivery nodes, improving treatment continuity outside hospitals.

In addition, a commercial shift towards fixed-dose combination products and bundled kits for neonatal therapy is expected to enhance standardization of care. The market is increasingly shifting away from reactive symptom control towards a proactive, phenotype-directed approach towards care that focuses on prolonged respiratory wellness in premature babies.

Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)

Market Shift	2020 to 2024
Regulatory Landscape	Guidelines have been introduced to ensure the protocols for BPD treatments are safe and effective.
Technological Advancements	Pharmacological therapies like bronchodilators, diuretics, corticosteroids and surfactant replacement therapies targeting lung function of preserved neonates.
Consumer Demand	Rising incidence of BPD in preterm babies; this leads to the increased use of pharmacological interventions and supportive care measures in neonatology units.
Market Growth Drivers	Increasing incidence of preterm births consequently leading to an increase in cases of BPD, advancement in neonatal care, and respiratory support technologies, and increasing healthcare expenditure in developed countries.
Sustainability	Early-stage solutions included the design of sustainable pharma formulations (eco-friendly materials), energy-efficient production.
Supply Chain Dynamics	Sensitivity to specialized suppliers of high-quality pharmaceuticals and medical devices used in the treatment of BPD, with a strong focus across companies to localize production to minimize supply-chain disruptions experienced due to global events.

Market Shift	2025 to 2035
Regulatory Landscape	In our opinion, the keeping under continuous scrutiny and possible bases for harmonization of all regulatory laws in view of the need for the balance between safety and innovation, and a process for rapid approval of new and innovative therapies for the same will be vital for optimal treatment of patients with unmet needs in the neonatal segment.
Technological Advancements	Emerging regenerative therapies, like stem cell the rapies and inhaled nitric oxide. These emergent therapies provide innovative strategies to manage BPD and enhance long-term pulmonary health in preterm infants.
Consumer Demand	There is a growing preference towards preventive strategies and less invasive treatment options due to improvements made in maternal health, neonatal management practices and advancements in prenatal care, and early detection methods to reduce the incidence and severity of BPD.
Market Growth Drivers	Growing healthcare access across emerging markets, an increase in investment for the research and development of innovative BPD therapeutics, ongoing technological advancements aimed at improving the efficacy of existing therapies, and an overall focus across the healthcare ecosystem on tackling the neonatal outcomes through collaborative efforts.
Sustainability	Implementation of sustainable manufacturing processes in line with global sustainability initiatives, along with eco-friendly treatment solutions to help minimize the environmental footprint of neonatal therapies.
Supply Chain Dynamics	Facilitation of local manufacturing by technology transfer and collaboration fosters decreased reliance on imports, enhances supply chain resilience, and provides timely response to health supply needs in neonatology, especially in the BPD management domain.

Country Wise Outlook

United States

Market Outlook

The United States leads the geographical split of the global market for bronchopulmonary dysplasia (BPD) treatment due to the high rate of preterm births and an established neonatal intensive care system as well as a robust pipeline of new innovative therapies for chronic lung disease in neonates.

Clinical management entails the application of oxygen therapy, mechanical ventilation, surfactants, corticosteroids, and, more recently, investigational biologics, with growing emphasis on personalized and preventive approaches.

Market Growth Factors

• High Survival Rate of Extremely Preterm Infants: Leading to increased BPD diagnosis and care needs.
• Advanced NICU Infrastructure with Nationwide Access to Surfactant and Ventilation Support: Standardizes treatment.
• Ongoing Trials of Regenerative Therapies (e.g., stem cells, IGF-1): Expanding therapeutic landscape.
• Established Neonatal Health Guidelines (AAP, NIH): Driving adoption of evidence-based interventions.
• Widespread Use of Postnatal Corticosteroids and Non-Invasive Ventilation Techniques: Improving outcomes.

Market Forecast

Country	CAGR (2025 to 2035)
United States	3.8%

India

Market Outlook

India’s BPD treatment market is growingat an increased pace owing to rising burden of preterm births, better NICU infrastructure, and rising utilization of standardized neonatal care protocols in both private and public hospitals. Rural areas have limited resources, but urban tertiary centers are up-taking non-invasive ventilation, surfactant therapy, and postnatal corticosteroids as part of the government and NGO initiatives.

Market Growth Factors

• High Preterm Birth Rate and Low Birth Weight Incidence: Sustains long-term BPD treatment demand.
• Government-Supported Neonatal Care Programs (e.g., FBNC): Improving treatment access.
• Rising Adoption of CPAP, HFNC, and Less Invasive Surfactant Methods: Enhancing survival and reducing severity.
• NGO and Donor Involvement in NICU Modernization: Facilitating access to modern therapies.
• Emerging Clinical Trials in Antioxidant and Immunomodulatory Agents: Expanding treatment horizon.

Market Forecast

Country	CAGR (2025 to 2035)
India	7.1%

Japan

Market Outlook

The Japan BPD treatment market features advanced technology, particularly in reducing ventilator use, enhancing maturation of the lung, and incorporating biomarker-based monitoring. Despite a low and decreasing birth rate and an increasingly aging population, Japan continues to pursue high-quality perinatal care, leading to improved survival of such infants born prematurely with BPD.

Market Growth Factors

• Strong NICU Capacity and Neonatal Survival Rates: Drives demand for chronic lung disease management.
• Clinical Use of Caffeine, Surfactant, and Antioxidants: Well-established in first-line protocols.
• Emphasis on Early Weaning from Oxygen and Mechanical Ventilation: Aligned with global best practices.
• Government-Funded Trials in Growth Factors and Stem Cell Therapy: Boosting pipeline innovation.
• Integration of Digital Lung Function Monitoring in NICUs: Supports individualized respiratory care.

Market Forecast

Country	CAGR (2025 to 2035)
Japan	4.5%

Germany

Market Outlook

The BPD treatment market in Germany is more advanced and systematized owing to infrastructure with well-equipped perinatal centers, strong emphasis on standardized protocols in NICU, and improved clinical research on lung-protective ventilation and pharmacological approaches. Antenatal steroids, surfactant therapy, and caffeine citrate are used widely and hospitals are working to reduce ventilator-induced lung injury.

Market Growth Factors

• High Level of NICU Care and Universal Neonatal Screening: Enables early diagnosis and intervention.
• Proactive Use of Lung-Protective Strategies in Preterm Infants: Reducing BPD severity.
• Government Support for Neonatal Research and Innovation: Encouraging biologic and stem cell trials.
• Strict Adherence to European Guidelines on Neonatal Respiratory Care: Ensures consistent clinical practice.
• Use of Inhaled Nitric Oxide and Minimally Invasive Surfactant Therapy (MIST): Gaining ground in tertiary centers.

Market Forecast

Country	CAGR (2025 to 2035)
Germany	4.3%

UK

Market Outlook

The UK BPD treatment market is growing at a vigorous pace due to allied NHS neonatal programs, a robust focus on premature infant outcome, and the in-clinic integration of non-invasive respiratory support, pharmacotherapy, and long-term pulmonary monitoring. This adds to therapeutic diversification and also falls in line with advances in neonatal care and ongoing trials of anti-inflammatory and growth factor-based therapies.

Market Growth Factors

• Government Commitment to Neonatal Health Outcomes: Supports funding and infrastructure development.
• High Adoption of CPAP and Less Invasive Surfactant Administration (LISA): Reducing ventilation-related injuries.
• Use of National Neonatal Audit Programme (NNAP) Data for Quality Improvement: Strengthens treatment pathways.
• Increasing Clinical Research in Postnatal Steroid Use and Bronchodilators: Enhancing evidence-based care.
• Rising Demand for Home Oxygen Therapy and Community Pulmonary Support: Improves long-term follow-up.

Market Forecast

Country	CAGR (2025 to 2035)
UK	5.0%

Market Outlook: Bronchopulmonary Dysplasia Treatment Market

By Drug Type

Bronchodilators lead due to fast relief and compatibility with neonatal drug protocols

Bronchodilators remain dominant in the BPD drug market due to their essential role in relieving airway obstruction and improving lung compliance in premature infants. These drugs are commonly used as first-line therapies in Level II and III NICUs given their rapid effects and safety record in the neonatal population. Their compatibility with other pharmacologic agents such as diuretics and corticosteroids has led to their inclusion in combination-based treatment regimens.

Hospital systems prefer bronchodilators due to their ease of administration and demonstrable short-term (hours to days) improvements in oxygenation that guide faster determinations regarding escalations in the use of ventilatory support or weaning protocols. And their use is not confined to high-resource settings, and is considered a staple of BPD management in both advanced and resource-limited geographies.

Adult-focused interventions were implemented, but their complexity, coupled with that of caring for an adult-patient-neonate, made their use more challenging compared to the already well adapted practice of neonatology, especially in hospitals where physicians already have extensive clinical experience working with neonates. With hospitals focusing on faster stabilization and shorter NICU stay, bronchodilators continue to play a key role in short term clinical outcomes.

Surfactant therapies emerge by targeting alveolar health and chronic lung recovery

Therapies targeting surfactant homeostasis are quickly emerging as a promising drug class and are anticipated to have a profound impact on the underlying pathophysiology of BPD, rather than just ameliorating symptoms. In contrast to bronchodilators or steroids, these therapies aim to restore the balance and function of endogenous surfactants, leading to improved alveolar stability and reduced risk of chronic lung remodeling.

More recent clinical research has been focused on optimizing dosage, timing, and delivery mechanisms of exogenous surfactants, aimed at increasing effectiveness in extremely low birth weight infants[41]. Neonatal research services analyzing personalized surfactant compositions based on genetic and environmental risk profiles are also strengthening this segment.

Moreover, combination therapies incorporating protein replacements and immunomodulators are paving the way for these to be integrated into lung regenerative care. With the market shifting towards outcome based neonatal treatment modalities, we see surfactant homeostasis therapies as a mainstay for long-term pulmonary health, particularly for infants with either recurrent oxygen dependency and/or ventilator exposure.

By Therapy Type

Supplemental oxygen therapy leads for its versatility across all BPD severity stages

Supplemental oxygen therapy remains the most universally implemented and clinically significant respiratory intervention for BPD treatment. The use of oxygen therapy is the first-line supportive treatment for preterm infants with immature lungs and inadequate gas exchange ability.

Oxygen is the most widely used therapeutic gas and as such, its use is applicable to infants across the spectrum of BPD, including mild-´bpd´ with no need for supplemental oxygen to severe manifestations where a great deal of supplemental oxygen is required for release from NICU but in need of respiratory follow-up for long-term care.

In hospitals and in pediatric critical care, accurately titrating O2 delivery limits hypoxemia and reduces early lung damage, enhancing the use of adjunct pharmacological interventions. Moreover, the versatility of oxygen therapy along the tiered landscape of resources-from sophisticated ventilator systems in tertiary centers to portable concentrators in nursing homes-has solidified its unequivocal place among standards of therapy.

While the guide toward a more integrated model of providing care evolves, oxygen therapy has remained the primary constant stabilizing agent in nearly every phase of adjunctive BPD management.

Stem cell therapy emerges as a regenerative path for reversing severe BPD

Stem cell therapy an emerging type of therapy in the BPD market, focusing on not just managing symptoms, but regenerating lung tissue. It seems preliminary studies showed potential for restoration of alveolar architecture, anti-inflammatory effects and for reversal of severe BPD fibrotic changes that were resistant to conventional therapy.

Stem cells, unlike traditional therapies, possess immunomodulatory and reparative abilities that can be crucial in treating chronic and irreversible lung injury from prolonged mechanical ventilation. Controlled trials of its use will be ramping up as neonatal research institutes and pediatric pulmonology centers rush to conduct the first mesenchymal stem cell infusions designed for neonatal safety and efficacy.

Limited at this point to specialized centers, the robust clinical potential and early success in compassionate-use settings are garnering commercial interest from biologics manufacturers. Given this, as the market starts to prioritize long-term restoration of the respiratory tract above short-term stabilization, stem cells is primed to be at the forefront of advanced BPD treatment strategies.

Competitive Outlook

The bronchopulmonary dysplasia (BPD) treatment market is being propelled by the growing frequency of preterm births and advancements made in neonatal intensive care. Bronchopulmonary dysplasia, or BPD, is a chronic lung disease that occurs in premature infants and often necessitates prolonged respiratory support and anti-inflammatory therapies.

Cell therapies for respiratory diseases and surfactant replacement innovations further bolster the market, along with a robust biologics pipeline. This is the most important aspect along with the types of stakeholders involved, such as pharmaceutical companies, medical device manufacturers, healthcare organization focusing on NICU facilities.

Market Share Analysis by Company

Company Name	Estimated Market Share (%)
Chiesi Farmaceutici S.p.A.	22-26%
AbbVie Inc.	16-20%
Medtronic plc	12-16%
Merck & Co., Inc.	8-12%
Philips Healthcare	5-9%
Other Companies (combined)	20-30%

Key Company Offerings and Activities

Company Name	Key Offerings/Activities
Chiesi Farmaceutici	Offers surfactant therapies such as Curosurf® widely used in neonates at risk of BPD.
AbbVie Inc.	Provides Synagis® (palivizumab) for RSV prevention, helping reduce BPD complications in high-risk infants.
Medtronic plc	Supplies neonatal ventilators and non-invasive respiratory support devices critical for BPD management.
Merck & Co., Inc.	Invests in R&D for inflammation-modulating therapies and neonatal care support products.
Philips Healthcare	Offers advanced neonatal care systems, including CPAP machines and incubators used in BPD prevention and care.

Key Company Insights

• Chiesi Farmaceutici S.p.A. (22-26%) Chiesi leads the BPD treatment market through its globally recognized surfactant products, supported by strong NICU partnerships and clinical expertise.
• AbbVie Inc. (16-20%) AbbVie supports BPD risk reduction with biologics targeting RSV infections, improving outcomes in preterm infants vulnerable to respiratory complications.
• Medtronic plc (12-16%) Medtronic provides essential respiratory support solutions in NICUs, helping manage BPD through mechanical ventilation and respiratory monitoring systems.
• Merck & Co., Inc. (8-12%) Merck’s pipeline includes anti-inflammatory and neonatal pulmonary support therapies aimed at long-term BPD treatment.
• Philips Healthcare (5-9%) Philips enables effective neonatal respiratory care with integrated monitoring, respiratory support, and environmental control systems.

Other Key Players Other contributors to the bronchopulmonary dysplasia treatment market include:

• Drägerwerk AG & Co. KGaA
• Viatris Inc. (Mylan)
• Mallinckrodt Pharmaceuticals
• Windtree Therapeutics
• Vapotherm Inc.

Table of Content

1. Executive Summary
2. Industry Introduction, including Taxonomy and Market Definition
3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2020 to 2024 and Forecast 2025 to 2035, including Historical Analysis and Future Projections
5. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035
   • By Drug Type
   • By Therapy Type
   • By End User
   • By Region
6. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Drug Type
   • Bronchodilators
   • Diuretics
   • Antibiotics
   • Steroids
   • Immunomodulators
   • Surfactant Homeostasis
7. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Therapy Type
   • Nitric Oxide Therapy
   • Protein replacement therapy
   • Stem Cell Therapy
   • Supplemental Oxygen
8. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by End User
   • Hospitals
   • Nursing Homes
   • Critical Care Centers
9. Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, by Region
   • North America
   • Latin America
   • East Asia
   • South Asia and Pacific
   • Western Europe
   • Eastern Europe
   • Middle East and Africa
10. North America Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
11. Latin America Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
12. East Asia Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
13. South Asia & Pacific Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
14. Western Europe Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
15. Eastern Europe Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
16. Middle East and Africa Sales Analysis 2020 to 2024 and Forecast 2025 to 2035, by Key Segments and Countries
17. Sales Forecast 2025 to 2035 by Drug Type, Therapy Type, and End User for 30 Countries
18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
19. Company Profile
    • Chiesi Farmaceutici S.p.A.
    • AbbVie Inc.
    • Medtronic plc
    • Merck & Co., Inc.
    • Philips Healthcare
    • Drägerwerk AG & Co. KGaA
    • Viatris Inc. (Mylan)
    • Mallinckrodt Pharmaceuticals
    • Windtree Therapeutics
    • Vapotherm Inc.